SERODUS ASA: CLINICAL TRIAL APPLICATION FILED FOR SER150 DIABETIC NEPHROPATHY

Oslo, February 18, 2015: Serodus ASA (Oslo Axess: SER) has today filed a Clinical Trial Application with the German authorities for a Phase IIa study on SER150 diabetic nephropathy.

“We are very pleased to reach this important milestone for our SER150 drug candidate and the study will be running during 2015 and 2016. Diabetic nephropathy is a severe complication in many diabetic patients where the kidney gradually loose its capability to maintain balance of all the body’s essential components such as protein, sodium and water. Treatment of the final stage of diabetic nephropathy is dialysis and we expect that SER150 will be a valuable drug to treat this condition and thus improve quality of life for diabetic patients” said Dr. Eva Steiness CEO of Serodus ASA

 

For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

 

Serodus ASA is a Norwegian drug development company, focusing on new therapeutic products for the treatment of cardiovascular diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.